Top Choice Medical Investment Co Inc

Topchoice Medical released its 2026 semi-annual report, achieving operating revenue of 1.586 billion yuan, up 4.1% year on year, and net profit attributable to shareholders of the listed company of 458 million yuan, up 32.7% year on year. The company's second-quarter net profit was 272 million yuan, and first-quarter net profit was 187 million yuan. Based on this calculation, second-quarter net profit rose 45% quarter on quarter.

Topchoice Medical announced that as of July 31, 2026, the company had repurchased 2.52 million shares, accounting for 0.5638% of total share capital, with a total repurchase amount of 88.75 million yuan, at a repurchase price range of 33.53 yuan to 36.66 yuan per share. In the first quarter of 2026, Topchoice Medical achieved revenue of 755 million yuan and net profit attributable to shareholders of 187 million yuan.

The A-share buyback wave is accelerating, with multiple industry leaders intensively disclosing progress. Panel leader BOE Technology had repurchased 500 million yuan of A-shares by July 31, reaching the lower limit of its buyback plan, taking only about half a month since the first repurchase on July 20. The company also simultaneously repurchased B-shares for 393 million Hong Kong dollars, shortly after completing a round of over 4 billion yuan in A-share buybacks at the end of May. Eye drug leader Shenyang Xingqi Pharmaceutical completed its 80 million to 100 million yuan buyback plan in just about a week, with the payment amount reaching 100 million yuan as of August 4. Innovative drug leader Hengrui Medicine had cumulatively paid 853 million yuan for buybacks as of July 31, while dental service leader Topchoice Medical's buyback amount reached 88.75 million yuan in the same period, approaching 90 percent of the 100 million yuan plan cap.

Topchoice Medical announced that as of now the company has repurchased 1.45 million shares, accounting for 0.3236% of total share capital, with a repurchase amount reaching 50.05 million yuan. The repurchase price range was 33.53 yuan to 35.71 yuan per share, and the repurchase amount has exceeded the lower limit of the buyback plan. In the first quarter of 2026, the company achieved revenue of 755 million yuan and net profit attributable to the parent of 187 million yuan.